Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Brain

‘Outrageous’: MEPs condemn pesticide companies for withholding toxicity data

Bayer and Syngenta accused of breaching legal obligations and unethical behaviour over brain toxicity studies

The Guardian - UK

Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

Trial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.

The Conversation

'MIND diet,' intended to prevent dementia, doesn't offer significant brain benefit, trial suggests

A clinical trial suggests that the MIND diet, which is intended to guard against dementia, offers little benefit over a standard diet in the short term.

LiveScience

From analysis to the latest developments in health,
read the most diverse news in one place.

Ex-Ajax and Manchester United goalie Van der Sar leaves intensive care after bleed around his brain

Former Netherlands goalkeeper Edwin van der Sar has been released from an intensive care unit in a Dutch hospital

The Independent UK

Footballer Shane Tuck 'heard voices before his death'

Former footballer and professional boxer Shane Tuck heard voices and had mental health concerns for years, an inquest into his death has been told.

AAP

How Trump's speech is warping MAGA minds

The implications stretch far beyond Donald Trump — and are ominous for American society

Salon

Why Josiah Harrell feels lucky (not sorry) after rare brain disease discovery canceled first UFC fight

A lot of things had to fall in line perfectly for Josiah Harrell to avoid a potentially life-threatening medical event.

USA Today Sports Media Group

Read news from The Economist, FT, and more,
with one subscription

Lilly applies for Alzheimer’s drug’s US approval after trial success

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

Tribune News Service

New drug found to slow Alzheimer’s hailed as turning point

Donanemab has been found to slow down the disease in a clinical trial.

The Independent UK

Optical illusion: Only a true detective can find a pencil among the carrots in 5 seconds

Optical illusion based puzzles are fun to solve as they trick you into not seeing something that is technically right in front of your eyes, with the help of using colors and patterns that fool your eyes and brain. However, if you are extra attentive and careful, then you could…

The Times of India

Everything we know about breakthrough Alzheimer’s drug Donanemab

Alzheimer’s disease is the most common cause of dementia in the UK

The Independent UK

Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

Evening Standard

‘Turning point’ in the fight against Alzheimer’s as drug found to slow disease

The results of a new trial were labelled as symbolic of ‘a new era where Alzheimer’s disease could become treatable’

The Independent UK

Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

An experimental Alzheimer's drug outperforms one just approved by the FDA

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

The Guardian - UK

What impact will Alzheimer’s drug donanemab have?

While it is not a cure, proof that drugs can alter course of disease is regarded as significant triumph

The Independent UK

‘Turning point in the fight against Alzheimer’s’ as drug found to slow disease

Donanemab has been found to slow down the disease in a clinical trial.

The Guardian - UK

‘I’m a chef and I forgot how to bake a cake’: why trauma often leads to brain fog and amnesia

Shock, stress and grief can have a devastating effect on memory – but there are ways to bring it back

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

‘I have mourned her for decades’: why first loves can shape our lives for ever

In our early romantic relationships, there is often a mismatch between the strength of our feelings and the stark reality. So why do they linger in our memories?

The Hindu

Doctors perform ‘awake brain surgery’ on a 30-year-old woman

Doctors perform ‘awake brain surgery‘ on a 30-year-old woman

The Guardian - AU

Is sleep the canary in the coalmine – a clue to the health of our minds?

Sleep disturbance is a recognised risk factor for developing a host of psychiatric disorders. Going to bed is the best thing you can do for your brain right now

The Conversation

Sleep deprivation benefited our ancestors, yet harms us now — but staying fit may help us cope

Humans need less sleep than our closest evolutionary relatives. However, we often sleep less than we need.

Tribune News Service

Former Sounder Jimmy Gabriel had CTE. His family is pushing for head safety in soccer.

TUKWILA, Wash. — Jimmy Gabriel told the best stories.

Tribune News Service

New Alzheimer’s drug is first to show it slows disease. But It’s facing a rocky rollout

Eisai Co.’s breakthrough Alzheimer’s drug — the first to show it slows the brain-destroying disease — is facing a rocky rollout as doctors grapple with logistical issues, insurance uncertainties and complicated safety testing requirements.

Newsroom.co.nz

Shaken baby syndrome needs a rethink

The term Abusive Head Trauma (Shaken baby syndrome) presupposes an action with malicious intent. These emotive labels should have no place masquerading as a medical diagnosis, argues Felicity Goodyear-Smith

1 … 273 274 275 276

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.